Want to see ES:ROVI full AI Analyst Report?
Total Valuation
Laboratorios Farmaceuticos Rovi has a market cap or net worth of €2.74B. The enterprise value is €4.16K.
Market Cap€2.74B
Enterprise Value€4.16K
Share Statistics
Laboratorios Farmaceuticos Rovi has 51,235,764 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding51,235,764
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Laboratorios Farmaceuticos Rovi’s return on equity (ROE) is 0.21 and return on invested capital (ROIC) is 16.52%.
Return on Equity (ROE)0.21
Return on Assets (ROA)0.15
Return on Invested Capital (ROIC)16.52%
Return on Capital Employed (ROCE)0.22
Revenue Per Employee333.10K
Profits Per Employee62.92K
Employee Count2,232
Asset Turnover0.78
Inventory Turnover1.01
Valuation Ratios
The current PE Ratio of Laboratorios Farmaceuticos Rovi is 21.0. Laboratorios Farmaceuticos Rovi’s PEG ratio is 7.71.
PE Ratio21.0
PS Ratio4.37
PB Ratio4.89
Price to Fair Value4.89
Price to FCF27.03
Price to Operating Cash Flow15.31
PEG Ratio7.71
Income Statement
In the last 12 months, Laboratorios Farmaceuticos Rovi had revenue of 743.48M and earned 140.44M in profits. Earnings per share was 2.75.
Revenue743.48M
Gross Profit451.65M
Operating Income173.14M
Pretax Income183.26M
Net Income140.44M
EBITDA203.52M
Earnings Per Share (EPS)2.75
Cash Flow
In the last 12 months, operating cash flow was 180.56M and capital expenditures -65.74M, giving a free cash flow of 114.82M billion.
Operating Cash Flow180.56M
Free Cash Flow114.82M
Free Cash Flow per Share2.24
Dividends & Yields
Laboratorios Farmaceuticos Rovi pays an annual dividend of €0.959, resulting in a dividend yield of 1.78%
Dividend Per Share€0.959
Dividend Yield1.78%
Payout Ratio39.49%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.66
52-Week Price Change4.40%
50-Day Moving Average57.27
200-Day Moving Average66.23
Relative Strength Index (RSI)28.46
Average Volume (3m)126.41K
Important Dates
Laboratorios Farmaceuticos Rovi upcoming earnings date is Jul 23, 2026, TBA (Confirmed).
Last Earnings DateMay 6, 2026
Next Earnings DateJul 23, 2026
Ex-Dividend Date―
Financial Position
Laboratorios Farmaceuticos Rovi as a current ratio of 3.14, with Debt / Equity ratio of 16.98%
Current Ratio3.14
Quick Ratio1.55
Debt to Market Cap0.03
Net Debt to EBITDA0.12
Interest Coverage Ratio60.84
Taxes
In the past 12 months, Laboratorios Farmaceuticos Rovi has paid 42.90M in taxes.
Income Tax42.90M
Effective Tax Rate0.23
Enterprise Valuation
Laboratorios Farmaceuticos Rovi EV to EBITDA ratio is 16.07, with an EV/FCF ratio of 27.23.
EV to Sales4.40
EV to EBITDA16.07
EV to Free Cash Flow27.23
EV to Operating Cash Flow17.65
Balance Sheet
Laboratorios Farmaceuticos Rovi has €97.39M in cash and marketable securities with €114.44M in debt, giving a net cash position of -€17.05M billion.
Cash & Marketable Securities€97.39M
Total Debt€114.44M
Net Cash-€17.05M
Net Cash Per Share-€0.33
Tangible Book Value Per Share€12.57
Margins
Gross margin is 63.23%, with operating margin of 23.29%, and net profit margin of 18.89%.
Gross Margin63.23%
Operating Margin23.29%
Pretax Margin24.65%
Net Profit Margin18.89%
EBITDA Margin27.37%
EBIT Margin23.29%
Analyst Forecast
The average price target for Laboratorios Farmaceuticos Rovi is €73.60, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target€73.60
Price Target Upside13.41% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast-3.44%
EPS Growth Forecast-5.45%